Drug Trial Radar · NCT05874414
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
98
Planned (sponsor's estimate)
Start
Aug 21, 2023
Primary completion
Dec 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- GenfitIndustry
- Sponsor type
- Industry
- First posted
- May 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy
Conditions
- Cholangiocarcinoma
Interventions
GNS561 + TrametinibDrug
GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicity (DLT) of GNS561 with trametinib (Phase 1b)Time frame: At the end of Cycle 1 (each Cycle is 21 days)
- Objective response rate (ORR) of the combination of GNS561 with trametinib (Phase 2a)Time frame: Up to 11 months (estimated)
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
LACN Aneheim Flagship Office
Los Angeles, California · Recruiting
Orlando Health
Orlando, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
University Of Chicago Medical Center
Chicago, Illinois · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Terminated
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania · Terminated
University of Texas, MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia · Recruiting
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Pan American Center for Oncology Trials, LLC
Rio Piedras, Puerto Rico, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.